Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer

Anticancer Research

Volumn 23, Issue 4, 2003, Pages 3453-3457

  Ogawa, Yoshinari ^a,b   Ishikawa, Tetsuro ^a   Chung, Sung Haw ^a   Ikeda, Katsumi ^a   Takashima, Tsutomu ^a   Onoda, Naoyoshi ^a   Nakata, Bunzo ^a   Nishiguchi, Yukio ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

Breast cancer; Chemotherapy; Cyclophosphamide; Metastasis; UFT

Indexed keywords

CYCLOPHOSPHAMIDE; UFT;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG RESPONSE; DRUG SCREENING; DYSGEUSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; INCIDENCE; LEUKOPENIA; NAUSEA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TIME; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PILOT PROJECTS; TEGAFUR; URACIL;

EID: 0043030099     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. A'Hern RP, Smith IE and Ebbs SR: Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Brit J Cancer 67: 801-805, 1993.
2. Hortobagyi GN: Treatment of breast cancer. New Engl J Med 339: 974-984, 1998.
3. MacMillian WE, Wobery WH and Welling PG: Pharmacokinetics of 5-fluorouracil in humans. Cancer Res 38: 3479-3483, 1978.
4. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG: A prospective randomized comparison of continuous infusion 5-fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7: 425-432, 1989.
5. Hansen R, Quebbeman E, Beatty P, Ritch P, Anderson T, Jenkins D, Frick J and Ausman R: Continuous 5-fluorouracil infusion in refractory carcinoma of breast. Breast Cancer Treat 10: 145-149, 1987.
6. Huans S, Pazdur R, Singhakowinta A, Samal B and Vaitkevicius VR: Low-dose continuous infusion of 5-fluorouracil, evaluation in advanced breast carcinoma. Cancer 63: 419-422, 1989.
7. Fujii S, Ikenaka K, Fukushima M and Shirasaka T: Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 69: 763-772, 1978.
8. Hirata K, Sasaki K, Yamamitsu S and Shirasaka T: A comparison of 5-fluorouracil concentration of 5-fluorouracil drip infusion versus orally UFT in plasma of same patients. Jpn J Cancer Chemother 20: 1409-1411, 1993.
9. Ota K, Taguchi T and Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22: 333-338, 1988.
10. Wada H, Hitomi S, Teramatsu T and West Japan Study Group for Lung Cancer Surgery: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 14: 1048-1054, 1996.
11. Weeler GP: Alkylating agents. In: Cancer Medicine (Holland JF, Frei III E eds). Philadelphia, Lee and Febinger, 1982.
12. Haga S, Shimizu T, Imamura H, Watanabe O, Kinoshita J, Fukushima M and Kajiwara T: Antitumor efficacy of combination chemotherapy with UFT and cyclophosphamide against human breast cancer xenografts in nude mice. Anticancer Res 19: 1791-1796, 1999.
13. Ogawa Y, Ishikawa T, Ogisawa K, Ikeda K, Nagatsuka I, Matsumura Y, Takashima T, Yashiro M, Onoda N, Nakata B, Kato Y and Hirakawa K: Three cases of metastatic breast cancer, resistant to pro-chemo and/or endocrine therapy, markedly improved with UFT and cyclophosphamide oral combination therapy. Jpn J Cancer Chemother 27: 2123-2127, 2000.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
15. National Cancer Institute Common Toxicity Criteria. NCI-CTC, ver.2.0: http://ctep.info.nih.gov/, Apr. 1999.
16. Hortobagyi GN: Endocrine treatment of breast cancer. In: Principles and Practice of Endocrinology and Metabolism, 2nd ed (Becker KL, ed). Philadelphia, J.B. Lippincott, 1995, pp1868-1892.
17. Stuart NS, Warwick J, Blackledge GR et al: A randomized phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer 32A: 1888-1892, 1996.
18. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P and Webster A: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma: Arimidex Study Group. Cancer 79: 730-739, 1997.
19. Henderson JC: Chemotherapy for metastatic disease. In: Breast Disease, 2nd ed (Harris JR, Hellman s, Henderson IC, Kinne DW, eds). Philadelphia, J.B.Lippincott, 1991, pp604-665.
20. Valero V, Holmes FA, Walters RS et al: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886-2894, 1995.
21. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-1867, 1996.
22. Hartman KY and Heidelberger C: Studies on fluorinated pyrimidines: XIII. Inhibition of thymidylate synthase. J Biol Chem 236: 3006-3018, 1961.
23. Suemasu K, Nomoto C and Higashi Y: Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT. Jpn J Cancer Chemother 9: 667-671, 1982.
24. Nakao S, Hasegawa H, Ishii T et al: The effect of UFT on lymphocyte subsets and lymphocyte response to PHA. Jpn J Chemother 14: 3157-3159, 1987.